Drug intelligence / Profile preview

SCV Seafood Allergy Vaccine

Development stage: Preclinical
Lead developer: Sementis
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

SCV Seafood Allergy Vaccine is a therapeutic vaccine candidate developed by Sementis for the treatment of seafood allergy. The vaccine utilizes the Sementis Copenhagen Vector (SCV) platform, which is a multi-antigen, multiplication-defective vaccinia-based viral vector. By delivering seafood allergens via this viral vector, the vaccine aims to modulate the patient's immune system to induce tolerance and reduce or eliminate allergic reactions upon exposure to seafood. It is currently in the preclinical stage of development.

Other names: Seafood Allergy Vaccine

Targets

TCR (T cell antigen receptor complex)Host cell surface components mediating Sementis Copenhagen Vector entry

Beyond the preview

Go deeper on SCV Seafood Allergy Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCV Seafood Allergy Vaccine.

Explore the full profile